复发性胰腺神经内分泌肿瘤:复发时机、模式及当前治疗
这项多中心研究纳入2000至2019年间4家机构接受根治性手术的1402例胰腺神经内分泌肿瘤患者,中位随访4.8年。5年远处复发累积发生率为13%,复发患者死亡风险为未复发者的2.89倍;复发后5年总生存率为74.6%。多数复发为远处转移并接受多种治疗,作者认为需前瞻性研究确定监测与治疗顺序策略。
要点
- 根治性术后5年远处复发累积发生率为13%,局部区域复发为1.4%,腹腔淋巴结复发为0.8%。
- 复发患者死亡风险为未复发患者的2.89倍(95%CI 2-4.1)。
- 复发后5年总生存率为74.6%(95%CI 67.4%-82.5%),多数复发为远处转移并接受多种治疗。
核心结论
- 术后复发不常见但降低生存,多数复发为远处转移并以多种疗法治;需要前瞻性研究建立监测策略与治疗顺序以控制疾病并延长生存。
研究设计与样本
- 多中心研究,纳入4家机构2000至2019年间接受根治性手术的胰腺神经内分泌肿瘤患者1402例,排除低分化肿瘤、肿瘤分级与分化未知、遗传综合征、切缘未知或R2状态、转移以及接受新辅助治疗或围术期死亡者。
主要发现
- 1402例中957例(74%)为1级、322例(25%)为2级、13例(1%)为3级肿瘤,中位随访4.8年(四分位距2-8.2年)。
- 5年远处复发累积发生率为13%(95%CI 11%-15.2%),局部区域复发为1.4%(95%CI 0.8%-2.3%),腹腔淋巴结复发为0.8%(95%CI 0.4%-1.5%)。
- 复发患者较未复发患者死亡风险增加,风险比为2.89(95%CI 2-4.1)。
- 复发后治疗包括生长抑素类似物111例(61.0%)、靶向治疗48例(26.4%)、肝脏导向治疗61例(33.5%)、肽受体放射性核素治疗30例(16.5%)和手术46例(25.3%),103例(57%)采用多种治疗。
- 首次复发后5年总生存率为74.6%(95%CI 67.4%-82.5%)。
局限性
- 原文结论指出需要前瞻性研究来建立监测策略和治疗顺序以控制疾病并延长生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to describe the pattern of recurrence, treatments received, as well the oncological outcomes, of pancreatic neuroendocrine tumors (PanNETs) following curative surgery. BACKGROUND: PanNETs recur in 10% to 15% of cases following surgery. Information on the natural history and management of recurring disease is lacking. MATERIALS AND METHODS: Patients with PanNET that underwent curative surgery at 4 institutions between 2000 and 2019 were identified. Patients with poorly differentiated tumors, unknown tumor grade and differentiation, hereditary syndromes, unknown margin or R2 status, metastatic, and those that had neoadjuvant treatment or perioperative mortality were excluded. Clinical variables were assessed including first site of recurrence, treatment received, and survival outcomes. RESULTS: A total of 1402 patients were included: 957 (74%) had grade 1, 322 (25%) had grade 2, and 13 (1%) had grade 3 tumors. Median follow-up was 4.8 years (interquartile range: 2-8.2 years). Cumulative incidence of recurrence at 5 years was 13% (95% CI: 11%-15.2%) for distant disease, 1.4% (95% CI: 0.8%-2.3%) for locoregional recurrence, and 0.8% (95% CI: 0.4%-1.5%) for abdominal nodal recurrence. Patients who recurred had 2.89 increased risk of death (95% CI: 2-4.1) as compared with patients who did not recur. Therapy postrecurrence included: somatostatin analogs in 111 (61.0%), targeted therapies in 48 (26.4%), liver-directed therapies in 61 (33.5%), peptide receptor radionuclide therapy in 30 (16.5%), and surgery in 46 (25.3%) patients. Multiple treatments were used in 103 (57%) cases. After the first recurrence, 5-year overall survival was 74.6% (95% CI: 67.4%-82.5%). CONCLUSIONS: Recurrence following surgery is infrequent but reduces survival. Most recurrences are distant and managed with multiple therapies. Prospective studies are needed to establish strategies for surveillance and the sequence of treatment to control the disease and prolong survival.
引用
- Pulvirenti A, Javed AA, Michelakos T, et al. Recurring Pancreatic Neuroendocrine Tumor: Timing and Pattern of Recurrence and Current Treatment. Ann Surg. 2023. PMID: 37796750. doi:10.1097/SLA.0000000000005809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。